WaveMan
WaveMan · Company
GTBP · Gt Biopharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GTBP GT Biopharma (GTBP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000109657
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
31
13F, latest reported quarter

GT Biopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for GT Biopharma, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Breen Michael Martin
Executive Chairman/Interim CEO
BUY
2023-04-11 SEC
50,000
$25.0K
-65.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.6% of the 656,218 shares held after it.
  • 1 other insider bought within 30 days.
  • 31 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman/Interim CEO Breen Michael Martin bought about $25.0K of GTBP on Apr 11, 2023; 1 other insider bought within 30 days and 31 funds added in the latest 13F quarter.
Ohri Manu
CFO & Secretary
BUY
2023-04-10 SECtraded 2023-04-06
50,000
$25.0K
-67.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 50,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 31 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO & Secretary Ohri Manu bought about $25.0K of GTBP on Apr 6, 2023, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 31 funds added in the latest 13F quarter.
Wendel Bruce
Director
BUY
2021-10-07 SECtraded 2020-12-22
441
$3.8K
-97.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 16, 2020.
  • The trade is 8.7% of the 5,083 shares held after it.
  • No other insider bought within 30 days.
  • 31 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wendel Bruce bought about $3.8K of GTBP on Dec 22, 2020; 31 funds added in the latest 13F quarter.
Wendel Bruce
Director
BUY
2021-10-07 SECtraded 2020-12-22
1,374
$12.2K
-97.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 16, 2020.
  • The trade is 29.6% of the 4,642 shares held after it.
  • No other insider bought within 30 days.
  • 31 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wendel Bruce bought about $12.2K of GTBP on Dec 22, 2020, the largest insider purchase at the company on our record; 31 funds added in the latest 13F quarter.
Wendel Bruce
Director
BUY
2021-10-07 SECtraded 2020-11-16
3,268
$10.3K
-97.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 3,268 shares held after it.
  • No other insider bought within 30 days.
  • 31 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wendel Bruce bought about $10.3K of GTBP on Nov 16, 2020, the largest insider purchase at the company on our record; 31 funds added in the latest 13F quarter.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
31 funds bought in last quarter
below 61% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.3% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
below 78% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch GTBP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+593.6%12M
-67%+452%+972%+1491%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GTBP: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
376,399 sh
$184.4K
GEODE CAPITAL MANAGEMENT, LLC
266,788 sh
$130.6K
VANGUARD FIDUCIARY TRUST CO
225,938 sh
$110.7K
49 WEALTH MANAGEMENT, LLC
128,000 sh
$62.7K
Everhart Financial Group, Inc.
100,000 sh
$49.0K

Congress trades in GTBP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GTBP planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

GTBP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$85.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$184.3K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$11.6K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$1.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Breen
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.7M
$1.6M
$739.3K
-97%
n/a
2024
$1.2M
$1.2M
$377.8K
-97%
n/a
2023
$1.5M
$1.3M
$1.1M
-92%
n/a
2022
$1.9M
$1.5M
$944.5K
-72%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 31 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GTBP financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2020-10-01 to 2021-09-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$14.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2017-12-31 (103 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
n/a
average equity is zero or negative
Return on assets
-77.2%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
1.67x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$223.7M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term debt only, 2017-12-31 (103 months older than the period end), minus cash 2026-06-30
FCF yield
-6.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$12.4M-$14.4M-$13.6M-$21.3M
Net income-$28.4M-$13.2M-$7.6M-$20.9M
EPS (diluted)-6.68-6.94-5.64-19.66
Operating cash flow-$12.9M-$12.9M-$8.9M-$15.2M
Cash$6.8M$4.0M$1.1M$5.7M
Dividends paid$229.0Kn/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

GTBP Stock Sonar score 3/7 axes

Find similar shapesCompare

GTBP ranks highest on financial health (99th percentile) and institutional and government (39th), and lowest on risk and compliance (36th), among Pharma & Biotech peers.

Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Institutional and government
39
Inputs
  • Funds adding, latest quarter31 · 39 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
36
Inputs
  • Short interest, % of float+15.3% · 25 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.0% · 48 pct, sector of 511
4 not measured: Profitability, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies